Advertisement

Postprandial anti-hyperglycemic effect of vitamin B6 (pyridoxine) administration in healthy individuals

  • Hyuk Hwa Kim
  • Yu-Ri Kang
  • Hwang-Yong Choi
  • Jung-Yun Lee
  • Jung-Bae Oh
  • Justin S. Kim
  • Young-Cheul Kim
  • Ki Won Lee
  • Young-In Kwon
Article
  • 8 Downloads

Abstract

Postprandial blood glucose lowering effect of vitamin B6 (pyridoxine) was evaluated in healthy individuals with normal blood glucose levels. Blood glucose levels were measured every 30 min for 2 h after oral sugar administration with or without 50 mg of pyridoxine. Pyridoxine significantly lowered the postprandial blood glucose levels at 30 min (from 165.95 ± 17.19 to 138.36 ± 20.43, p < 0.01) and 60 min (from 131.40 ± 17.20 to 118.50 ± 15.95) after administration. In addition, the area under the concentration–time curve (AUCt) was reduced by about 8.3% (from 257.08 ± 22.38 to 235.71 ± 12.33, p < 0.05) and the maximum concentration of blood glucose (Cmax) was reduced by about 13.8% (from 165.95 ± 17.19 to 143.07 ± 11.34, p < 0.01) when compared with those of the control group. Our findings suggest that pyridoxine supplementation may be beneficial for controlling postprandial hyperglycemia.

Keywords

Pyridoxine Pyridoxine hydrochloride Vitamin B6 Anti-hyperglycemic effects Healthy individuals Postprandial hyperglycemia 

Notes

Acknowledgements

This research was financially supported by the Ministry of Trade, Industry, and Energy (MOTIE), Korea, under the “Regional Specialized Industry Development Program” supervised by the Korea Institute for Advancement of Technology (KIAT).

Compliance with ethical standards

Conflicts of interest

The authors declare no conflict of interest.

References

  1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 35: S64–S71 (2012)Google Scholar
  2. Bender DA. The Vitamins. pp. 132–187. In: Introduction to human nutrition. Gibney MJ, Lanham-New SA, Cassidy A, Vorster HH. (ed). John Wiley & Sons, Inc., Hoboken, NJ, USA (2009)Google Scholar
  3. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul. Health Metr. 8: 29 (2010)CrossRefGoogle Scholar
  4. Centers for Disease Control and Prevention. Diabetes Report Card 2014. Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, GA, USA (2015)Google Scholar
  5. Hou CT, Wu YH, Huang PN, Cheng CH, Huang YC. Higher plasma pyridoxal 5′-phosphate is associated with better blood glucose responses in critically ill surgical patients with inadequate vitamin B-6 status. Clin. Nutr. 30: 478–483 (2011)CrossRefGoogle Scholar
  6. Hsu CC, Cheng CH, Hsu CL, Lee WJ, Huang SC, Huang YC. Role of vitamin B6 status on antioxidant defenses, glutathione, and related enzyme activities in mice with homocysteine-induced oxidative stress. Food Nutr. Res. 59: 25702 (2015)CrossRefGoogle Scholar
  7. Kannan K, Jain SK. Effect of vitamin B6 on oxygen radicals, mitochondrial membrane potential, and lipid peroxidation in H2O2-treated U937 monocytes. Free Radic. Biol. Med. 36: 423–428 (2004)CrossRefGoogle Scholar
  8. Kim HW, Kang YR, Lee JY, Chang HB, Lee KW, Apostolidis E, Kwon YI. The postprandial anti-hyperglycemic effect of pyridoxine and its derivatives using in vitro and in vivo animal models. Nutrients. 10: 285–296 (2018)CrossRefGoogle Scholar
  9. Morris MS, Picciano MF, Jacques PF, Selhub J. Plasma pyridoxal 5-phosphate in the US population: the National Health and Nutrition Examination Survey, 2003–20041–4. Am. J. Clin. Nutr. 87: 1446–1454 (2008)CrossRefGoogle Scholar
  10. Odum EP, Wakwe VC. Plasma concentrations of water soluble vitamins in metabolic syndrome subjects. Niger. J. Clin. Pract. 15: 442–447 (2012)CrossRefGoogle Scholar
  11. Roth-Maier DA, Kettler SI, Kirchgessner M. Availability of vitamin B6 from different food sources. Int. J. Food Sci. Nutr. 53: 171–179 (2002)CrossRefGoogle Scholar
  12. Van de Laar FA. Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. Vasc. Health Risk Manag. 4: 1189–1195 (2008)CrossRefGoogle Scholar
  13. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care. 28: 154–163 (2005)CrossRefGoogle Scholar
  14. Wei EK, Giovannucci E, Selhub J, Fuchs CS, Hankinson SE, Ma J. Plasma vitamin B6 and the risk of colorectal cancer and adenoma in women. J. Natl. Cancer Inst. 97: 684–692 (2005)CrossRefGoogle Scholar

Copyright information

© The Korean Society of Food Science and Technology 2019

Authors and Affiliations

  1. 1.Department of Agricultural BiotechnologySeoul National UniversitySeoulKorea
  2. 2.Department of Food and NutritionHannam UniversityDaejeonKorea
  3. 3.Institute of KPBKunpoong Bio Co., LtdSeoulKorea
  4. 4.Department of NutritionUniversity of MassachusettsAmherstUSA

Personalised recommendations